ArticleOncogenesis2019
Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer.
Yaping Lv et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
31 papers cite it
this papercites it